New Data, New Opportunities, and New Clinical Challenges Using Immunotherapies for TNBC

With pembrolizumab plus chemotherapy now approved for PD-L1–positive advanced TNBC, how can we leverage this regimen for treating patients with this challenging disease? Here’s my take.

Heather McArthur, MD, MPH Released: November 20, 2020

With sacituzumab govitecan, pembrolizumab, and atezolizumab all now approved for advanced TNBC, how do we sequence these agents and how does a BRCA1/2 mutation affect sequencing decisions? Here are my thoughts.

Kevin Kalinsky, MD, MS Released: December 23, 2020

Download these slides for expert perspectives on incorporating immune checkpoint inhibitor–based therapy into optimal management of advanced/metastatic TNBC, including the biologic rationale, biomarkers for response, and key trial data.

Rita Nanda, MD Released: December 8, 2020

Download these slides for an expert-curated review of the latest developments in using immune checkpoint inhibitor–based therapy to treat early-stage TNBC, followed by insights into monitoring and management of immune-related adverse events.

Heather McArthur, MD, MPH Rita Nanda, MD Released: December 8, 2020

Download these slides for expert insights into approved and emerging antibody–drug conjugates for managing TNBC, including sacituzumab govitecan, ladiratuzumab vedotin, and more.

Kevin Kalinsky, MD, MS Released: December 8, 2020

Download this short summary slideset of key takeaways from a CCO live Webinar for an expert overview on incorporating immune checkpoint inhibitors and antibody–drug conjugates into optimal management of early-stage and advanced TNBC.

Kevin Kalinsky, MD, MS Heather McArthur, MD, MPH Rita Nanda, MD Released: December 16, 2020

In this interactive recording of a live CCO Webinar, a dynamic expert panel discusses the latest data on optimal use of immune checkpoint inhibitors and antibody–drug conjugates for treating patients with early-stage through metastatic TNBC.

Heather McArthur, MD, MPH
Program Director Kevin Kalinsky, MD, MS Rita Nanda, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ ABIM MOC: maximum of 1.25 Medical Knowledge MOC point(s) Released: January 22, 2021 Expired: January 21, 2022

Immune Checkpoint Inhibitor in Advanced TNBC (26 minutes)

Immune Checkpoint Inhibitor in Early-Stage TNBC (27 minutes)

Antibody–Drug Conjugates in TNBC (26 minutes)